173 related articles for article (PubMed ID: 27615706)
1. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Donovan LE; Arnal AV; Wang SH; Odia Y
CNS Oncol; 2016 Oct; 5(4):203-9. PubMed ID: 27615706
[TBL] [Abstract][Full Text] [Related]
2. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
Rotondo F; Cusimano M; Scheithauer BW; Coire C; Horvath E; Kovacs K
Hormones (Athens); 2012; 11(1):94-100. PubMed ID: 22450349
[TBL] [Abstract][Full Text] [Related]
3. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
[TBL] [Abstract][Full Text] [Related]
4. New targeted therapies in pituitary carcinoma resistant to temozolomide.
Jouanneau E; Wierinckx A; Ducray F; Favrel V; Borson-Chazot F; Honnorat J; Trouillas J; Raverot G
Pituitary; 2012 Mar; 15(1):37-43. PubMed ID: 21858654
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
6. Refractory pituitary adenoma: a novel classification for pituitary tumors.
Dai C; Feng M; Liu X; Ma S; Sun B; Bao X; Yao Y; Deng K; Wang Y; Xing B; Lian W; Zhong D; Ma W; Wang R
Oncotarget; 2016 Dec; 7(50):83657-83668. PubMed ID: 27845901
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
Ma DJ; Galanis E; Anderson SK; Schiff D; Kaufmann TJ; Peller PJ; Giannini C; Brown PD; Uhm JH; McGraw S; Jaeckle KA; Flynn PJ; Ligon KL; Buckner JC; Sarkaria JN
Neuro Oncol; 2015 Sep; 17(9):1261-9. PubMed ID: 25526733
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
9. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
11. Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin AL; Sum MW; DeAngelis LM
Neuro Oncol; 2016 Oct; 18(10):1350-6. PubMed ID: 27106409
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Kamiya-Matsuoka C; Cachia D; Waguespack SG; Crane CH; Mahajan A; Brown PD; Nam JY; McCutcheon IE; Penas-Prado M
Pituitary; 2016 Aug; 19(4):415-21. PubMed ID: 27106209
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
17. Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma.
Mendola M; Passeri E; Ambrosi B; Corbetta S
J Clin Endocrinol Metab; 2014 Aug; 99(8):2623-4. PubMed ID: 24823463
[No Abstract] [Full Text] [Related]
18. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract][Full Text] [Related]
19. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.
Lin AL; Jonsson P; Tabar V; Yang TJ; Cuaron J; Beal K; Cohen M; Postow M; Rosenblum M; Shia J; DeAngelis LM; Taylor BS; Young RJ; Geer EB
J Clin Endocrinol Metab; 2018 Oct; 103(10):3925-3930. PubMed ID: 30085142
[TBL] [Abstract][Full Text] [Related]
20. Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastases.
Shastri BR; Nanda A; Fowler M; Levine SN
World Neurosurg; 2013 Feb; 79(2):404.e11-6. PubMed ID: 22079280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
